Literature DB >> 20689269

Lessons from a case of oromandibular mucormycosis treated with surgery and a combination of amphotericin B lipid formulation plus caspofungin.

Mario Ojeda-Uribe1, Raoul Herbrecht, Marie Hélène Kiefer, Philippe Schultz, Jorge Chain, Marie-Pierre Chenard, Jean Marie Servant, Christian Debry.   

Abstract

A rare case of oromandibular Rhizopus oryzae infection is described in a 55-year-old woman with acute myeloid leukaemia and decompensated diabetes mellitus. The infection developed during induction chemotherapy when the patient was neutropenic. She was treated with a combination of amphotericin B lipid formulation and caspofungin plus surgery. Debridement surgery included excision of the lower lip, chin, floor of the mouth, a portion of the tongue, as well as mandibular resection at the level of the horizontal branches. Eight weeks of combined antifungal therapy were followed by secondary prophylaxis with amphotericin B lipid formulation during consolidation chemotherapy after achieving complete response of both leukaemia and mucormycosis. Reconstructive surgery was carried out including insertion of a new biomaterial porous mandibular prosthesis, which showed excellent functionality after long-term follow-up, followed by several plastic surgery procedures once good tolerability and no adverse effects of the prosthesis were observed. This case shows that a well-coordinated multidisciplinary approach is critical to increase the chances of clinical success in this life-threatening infection.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20689269     DOI: 10.1159/000315675

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  5 in total

Review 1.  How I treat mucormycosis.

Authors:  Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Blood       Date:  2011-05-26       Impact factor: 22.113

Review 2.  Current Treatment Options for COVID-19 Associated Mucormycosis: Present Status and Future Perspectives.

Authors:  Yasasve Madhavan; Kadambari Vijay Sai; Dilip Kumar Shanmugam; Aashabharathi Manimaran; Karthigadevi Guruviah; Yugal Kishore Mohanta; Divyambika Catakapatri Venugopal; Tapan Kumar Mohanta; Nanaocha Sharma; Saravanan Muthupandian
Journal:  J Clin Med       Date:  2022-06-23       Impact factor: 4.964

3.  How should we manage a patient with invasive mucoromycosis who develops life-threatening reaction to amphotericin B? Report of two cases and literature review.

Authors:  Fereshte Sheybani; HamidReza Naderi; MohammadReza Sarvghad; MohammadJavad Ghabouli; Mahnaz Arian
Journal:  Med Mycol Case Rep       Date:  2015-03-11

4.  Neck infection after allogenic hematopoietic progenitors transplantation.

Authors:  J Mensa; C Dueñas Gutiérrez; C Cardozo; L Rodríguez Fernández; M Kestler; P Muñoz; E Bouza
Journal:  Rev Esp Quimioter       Date:  2020-02-14       Impact factor: 1.553

5.  Combination of amphotericin B and caspofungin in the treatment of mucormycosis.

Authors:  Marwa Gargouri; Chakib Marrakchi; Wiem Feki; Slim Charfi; Imed Maaloul; Dorra Lahiani; Emna Elleuch; Makram Koubaa; Zineb Mnif; Ali Ayadi; Tahiya Boudawara; Mounir Ben Jemaa
Journal:  Med Mycol Case Rep       Date:  2019-09-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.